Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial.

ABSTRACT:

Objective

To assess the efficacy and safety of edaravone dexborneol, a multitarget brain cytoprotectant composed of antioxidant and anti-inflammatory ingredients, in improving functional outcomes among patients with acute ischaemic stroke undergoing endovascular thrombectomy.

Design

Multicentre, double blind, randomised, placebo controlled trial.

Setting

106 hospitals in China between March 2022 and May 2023.

Participants

1362 patients with clinically diagnosed acute ischaemic stroke within 24 hours of symptom onset, aged 18-80 years, with a National Institutes of Health Stroke Scale (NIHSS) score of 6-25 and an Alberta Stroke Program Early Computed Tomography Score (ASPECTS) of 6-10, confirmed large vessel occlusion in the anterior circulation, and planned end

SUBMITTER: Wang C 

PROVIDER: S-EPMC12776454 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature